Impact of probiotic supplementation in a patient with type 2 diabetes on glycemic and lipid profile.

Autor: Ziegler MC; Programa de Pós-Graduação Em Nutrição e Alimentos (PPGNA), Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil. Electronic address: mairacorneliziegler@hotmail.com., Garbim Junior EE; Programa de Pós-Graduação Em Nutrição e Alimentos (PPGNA), Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil., Jahnke VS; Escola da Saúde, Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil., Lisbôa Moura JG; Programa de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Zip code 90610-000, RS, Brazil., Brasil CS; Escola da Saúde, Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil., Schimitt da Cunha PH; Escola da Saúde, Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil., Lora PS; Programa de Pós-Graduação Em Nutrição e Alimentos (PPGNA), Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil; Escola da Saúde, Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil., Gemelli T; Programa de Pós-Graduação Em Nutrição e Alimentos (PPGNA), Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil; Escola da Saúde, Universidade Do Vale Do Rio Dos Sinos, São Leopoldo, Zip code 93022-750, RS, Brazil.
Jazyk: angličtina
Zdroj: Clinical nutrition ESPEN [Clin Nutr ESPEN] 2022 Jun; Vol. 49, pp. 264-269. Date of Electronic Publication: 2022 Apr 09.
DOI: 10.1016/j.clnesp.2022.04.002
Abstrakt: Background & Aims: Type 2 diabetes mellitus (T2DM) is a progressive chronic non-communicable disease associated with various comorbidities; it is considered complex and therefore multifactorial strategies must be applied to reduce the associated risks. The aim of this before-and-after clinical trial was to evaluate the effects of adjuvant supplementation with probiotics in patients with T2DM.
Methods: The study included 20 patients aged >30 years with T2DM who were overweight or obese. The patients were administered probiotic supplements daily for 90 days, which consisted of probiotics Bacillus clausii microorganism strain. The patients' blood glucose parameters, lipid and intestinal microbiota profiles, blood pressure (BP), drug therapy, body mass index (BMI), and food tissue were evaluated.
Results: At the end of the study, we observed a statistically significant difference in blood glucose, increased high density lipoprotein (HDL) plasma levels, and improved intestinal microbiota profiles among the patients included in this study.
Conclusions: The results showed that probiotic supplementation significantly reduced fasting glycemia and promoted an improvement in their lipid profiles and intestinal health. These findings are promising and the use of probiotics may be an appropriate adjuvant therapy for glycemic control in patients with T2DM.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: